SCHEMBL14604838

SCHEMBL14604838

O=C(Nc1ccc2cc(-c3ccc4c(c3)NCC4)ccc2c1)c1ccsc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KCNK3 O14649 1/20 0.44
▸ KCNK9 Q9NPC2 1/20 0.44
▸ MAPK14 Q16539 5/20 0.42
▸ HPGD P15428 1/20 0.42
▸ PLAU P00749 2/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ CFTR P13569 1/20 0.41
▸ F2 P00734 1/20 0.41
▸ PLG P00747 1/20 0.41
▸ PLAT P00750 1/20 0.41
▸ KLKB1 P03952 1/20 0.41
▸ PRSS1 P07477 1/20 0.41
▸ SLC2A1 P11166 2/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ TNIK Q9UKE5 2/20 0.39
▸ MELK Q14680 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2382466 0.82 CRBN (0.51) KCNK3KCNK9MAPK14HPGDNPC1
SCHEMBL2380778 0.78 TLK2 (0.48) KCNK3KCNK9MAPK14HPGDNPC1
SCHEMBL2382186 0.78 ESR1 (0.53) KCNK3KCNK9MAPK14HPGDNPC1
SCHEMBL2382379 0.76 NPC1 (0.58) KCNK3KCNK9HPGDNPC1RAB9A
SCHEMBL2382404 0.74 NPC1 (0.60) NPC1RAB9AKMT2A
SCHEMBL12297409 0.72 KCNK3 (0.57) KCNK3KCNK9MAPK14HPGDNPC1
SCHEMBL2380902 0.72 KDR (0.50) KCNK3KCNK9MAPK14MELK
SCHEMBL2380312 0.72 CDK7 (0.45) KCNK3KCNK9MAPK14HPGDNPC1
SCHEMBL2380306 0.71 MAPK14 (0.49) KCNK3KCNK9MAPK14HPGDNPC1
SCHEMBL2380402 0.69 NPC1 (0.50) KCNK3KCNK9PLAUNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070054903-A1 Bis-aryl kinase inhibitors and method AMGEN INC. (US) 2007-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054903-A1 Bis-aryl kinase inhibitors and method HGF, MET, BLK KCNK3 1810/4885KCNK9 2541/4885MAPK14 292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback